RLN2 and colitis: To determine whether Homo inhibits the occurrence and development of colitis through the MMP9-RLN2 signaling pathway, the MMP9-specific inhibitor (IN-1, 1 mg/kg) in combination with Homo (50 mg/kg) was utilized to investigate its impact on colitis in mice.